Collective Family Office LLC Purchases 123 Shares of Eli Lilly and Company (NYSE:LLY)


Share on StockTwits

Collective Family Office LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 7.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,837 shares of the company’s stock after purchasing an additional 123 shares during the quarter. Collective Family Office LLC’s holdings in Eli Lilly and were worth $343,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its position in Eli Lilly and by 2.2% during the first quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,752 shares of the company’s stock worth $701,000 after purchasing an additional 82 shares during the period. BFT Financial Group LLC lifted its holdings in shares of Eli Lilly and by 29.4% in the first quarter. BFT Financial Group LLC now owns 3,484 shares of the company’s stock worth $651,000 after acquiring an additional 791 shares during the last quarter. Redpoint Investment Management Pty Ltd lifted its holdings in shares of Eli Lilly and by 0.6% in the first quarter. Redpoint Investment Management Pty Ltd now owns 23,120 shares of the company’s stock worth $4,319,000 after acquiring an additional 142 shares during the last quarter. Norway Savings Bank lifted its holdings in shares of Eli Lilly and by 5.5% in the first quarter. Norway Savings Bank now owns 7,831 shares of the company’s stock worth $1,463,000 after acquiring an additional 405 shares during the last quarter. Finally, Royal London Asset Management Ltd. increased its stake in shares of Eli Lilly and by 3.2% in the first quarter. Royal London Asset Management Ltd. now owns 876,905 shares of the company’s stock valued at $163,823,000 after buying an additional 27,483 shares during the period. 75.59% of the stock is owned by institutional investors and hedge funds.

In other news, major shareholder Lilly Endowment Inc sold 125,284 shares of the firm’s stock in a transaction on Monday, March 8th. The stock was sold at an average price of $209.69, for a total transaction of $26,270,801.96. Following the completion of the sale, the insider now directly owns 110,422,933 shares of the company’s stock, valued at approximately $23,154,584,820.77. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.09% of the company’s stock.

Several research firms have recently issued reports on LLY. Cowen upped their price objective on Eli Lilly and from $195.00 to $235.00 and gave the company an “outperform” rating in a research note on Friday, February 12th. Truist Securities increased their target price on shares of Eli Lilly and from $215.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, March 22nd. Truist increased their target price on shares of Eli Lilly and from $200.00 to $215.00 in a research report on Monday, February 1st. Barclays increased their target price on shares of Eli Lilly and from $190.00 to $232.00 and gave the company an “overweight” rating in a research report on Monday, February 1st. Finally, Morgan Stanley increased their price target on Eli Lilly and from $190.00 to $217.00 and gave the stock an “overweight” rating in a report on Thursday, February 4th. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $193.88.

Shares of NYSE:LLY opened at $185.92 on Friday. The company has a current ratio of 1.36, a quick ratio of 1.06 and a debt-to-equity ratio of 3.27. The stock’s fifty day simple moving average is $192.61 and its two-hundred day simple moving average is $172.70. Eli Lilly and Company has a 1-year low of $129.21 and a 1-year high of $218.00. The stock has a market cap of $178.30 billion, a PE ratio of 30.38, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Thursday, January 28th. The company reported $2.75 earnings per share for the quarter, beating the consensus estimate of $2.35 by $0.40. Eli Lilly and had a return on equity of 166.45% and a net margin of 24.01%. The business had revenue of $7.44 billion for the quarter, compared to analysts’ expectations of $7.27 billion. During the same period last year, the business earned $1.73 EPS. The business’s revenue was up 21.7% on a year-over-year basis. On average, sell-side analysts forecast that Eli Lilly and Company will post 7.56 earnings per share for the current fiscal year.

Eli Lilly and Profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Recommended Story: Cash Flow Analysis in Stock Selection

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.